Symbols

ELUT

Elutia·NASDAQ

--(--)

ELUT fundamentals

ELUT Q4 2025 Earnings

Elutia (ELUT) released its earnings on Mar 11, 2026: revenue was 3.27M (YoY -40.18%), missed estimates; EPS was 1.48 (YoY +669.23%), beat estimates.

Revenue / YoY

3.27M

-40.18%

EPS / YoY

1.48

+669.23%

Report date

Mar 11, 2026

ELUT Earnings Call Summary for Q4,2025

Breakthrough Product Pipeline: NXT-41x targeting 15%-20% post-surgical infection rates in breast reconstruction, with FDA submission for 41 base matrix in Q1 2026.
Financial Resilience: $44.4M cash post-BioEnvelope sale, enabling debt-free development and 16% YoY revenue growth to $3.3M.
Strategic Focus: Divesting SimpliDerm to concentrate resources on 41x, supported by 144 VAC engagements and KOL partnerships.
Market Differentiation: 66.8% gross margin validates cost leadership, while 41x's 30-day antibiotic elution addresses unmet need in high-risk mastectomy patients.

Earnings

EPS

Revenue

Revenue & Expenses

ELUT has released its 2025 Q4 earnings report, with revenue of 3.27M, reflecting a YoY change of 16.16%, and net profit of 70.79M, showing a YoY change of 881.27%. The Sankey diagram below clearly presents ELUT's revenue sources and cost distribution.

Key Indicators

Elutia (ELUT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Elutia (ELUT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Elutia (ELUT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Elutia (ELUT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown